Development of reactive arthritis and resistance to erythromycin and rifampin in a foal during treatment for Rhodococcus equi pneumonia.
Department of Clinical Studies, University of Guelph, Ontario, Canada.
D G
DG
Kenney
S C
SC
Robbins
J F
JF
Prescott
A
A
Kaushik
J D
JD
Baird
D000193:Actinomycetales Infections / Q000150:complications / Q000188:drug therapy / Q000662:veterinary*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D000904:Antibiotics, Antitubercular / Q000494:pharmacology / Q000627:therapeutic use; D016918:Arthritis, Reactive / Q000175:diagnosis / Q000209:etiology / Q000662:veterinary*; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D004917:Erythromycin / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006734:Horse Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D006736:Horses; D008168:Lung / Q000382:microbiology / Q000473:pathology; D018410:Pneumonia, Bacterial / Q000150:complications / Q000188:drug therapy / Q000662:veterinary*; D012217:Rheumatoid Factor / Q000032:analysis; D016929:Rhodococcus equi / Q000187:drug effects* / Q000302:isolation & purification; D012293:Rifampin / Q000494:pharmacology / Q000627:therapeutic use; D013582:Synovial Fluid / Q000737:chemistry
D000900:Anti-Bacterial Agents; D000904:Antibiotics, Antitubercular; D004917:Erythromycin; D012217:Rheumatoid Factor; D012293:Rifampin